# IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Source: https://onco.cc/trials/nct04086264/  
OnCo record `nct04086264` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Azacitidine, Pivekimab sunirine and Venetoclax in acute myeloid leukaemia, run by AbbVie, active and no longer recruiting.

## Summary

IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia is a phase 1/2 interventional study registered as NCT04086264 by AbbVie, with 218 participants enrolled, started 2019-11-06 and due to reach its primary completion in 2027-02. Interventions recorded: Azacitidine, IMGN632 and Venetoclax.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04086264
- Phase: 1/2
- Setting: A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
- Sponsor: AbbVie
- Enrolled: 218

## Sources

- ClinicalTrials.gov NCT04086264: https://clinicaltrials.gov/study/NCT04086264

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [Azacitidine](https://onco.cc/drugs/azacitidine/), [Pivekimab sunirine](https://onco.cc/drugs/pivekimab-sunirine/), [Venetoclax](https://onco.cc/drugs/venetoclax/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)

---
JSON: https://onco.cc/api/v1/entities/nct04086264.json